Core Viewpoint - TELA Bio, Inc. has successfully closed a public offering of 14,670,000 shares of common stock, raising gross proceeds of $46 million, which will be utilized for various corporate purposes [1][2]. Group 1: Offering Details - The public offering price was set at $2.25 per share, with an additional option for investors to purchase pre-funded warrants at a price of $2.2499 each, allowing for the purchase of 5,800,000 shares [1]. - The offering included the full exercise of the underwriters' option to purchase additional shares [1]. - Canaccord Genuity and Lake Street Capital Markets served as joint bookrunners for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, which encompass sales and marketing, research and development, general and administrative expenses, working capital, and capital expenditures [2]. Group 3: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company that focuses on innovative soft-tissue reconstruction solutions, aiming to optimize clinical outcomes by preserving and restoring the patient's anatomy [5]. - The company emphasizes the use of advanced technologies that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [5].

MALVERN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, w ...

Core Viewpoint - TELA Bio, Inc. is set to report its third quarter 2024 financial results on November 7, 2024, and will host a conference call and webcast to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The third quarter 2024 financial results will be announced on November 7, 2024 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day to discuss the financial results [1]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [3]. - The company aims to optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy [3]. - TELA Bio is committed to providing advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [3].

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.23, delivering a surprise of 52.08%. Over the last four quarters, the company has surpass ...

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Reported revenue of $16.1 million in the second quarter, representing growth of 11% over the prior year period of 2023; Appointed Greg Firestone as Chief Commercial Officer on May 20, 2024 to drive our next phase of revenue g ...

Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving and restoring the patient's own anatomy [3] Recent Developments - The Compensation Committee of TELA Bio's Board of Directors approved inducement grants of restricted stock units covering 16,000 shares to nine newly-hired employees, with a grant date of August 6, 2024 [1] - The restricted stock units will vest in equal annual installments over four years, contingent on each individual's continued service with TELA Bio [2]

Core Viewpoint - TELA Bio, Inc. is set to report its second quarter 2024 financial results on August 12, 2024, and will host a conference call and webcast to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The second quarter 2024 financial results will be reported on August 12, 2024 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day to discuss the financial results [1]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [3]. - The company aims to optimize clinical outcomes by preserving and restoring the patient's own anatomy while minimizing long-term exposure to synthetic materials [3].

MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff jo ...

"I would also like to extend my deepest appreciation to Peter Murphy for his many contributions to TELA Bio and guiding us through our initial periods of continuous growth," said Antony Koblish. "We are confident that Greg's leadership will build upon and sustain this success." To learn more about TELA Bio, visit telabio.com About TELA Bio, Inc. MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial- stage medical technology company focused on providing innovative soft-ti ...

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial- stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbu ...